key: cord-0793566-yrka7iin
authors: Torres Acosta, Manuel A.; Singer, Benjamin D.
title: Pathogenesis of COVID-19-induced ARDS: implications for an aging population
date: 2020-08-03
journal: Eur Respir J
DOI: 10.1183/13993003.02049-2020
sha: 5c91a1f1a08d86e9e648b4f36d8bd963ecc5ddb8
doc_id: 793566
cord_uid: yrka7iin

The coronavirus disease (COVID)-19 pandemic has elicited a swift response by the scientific community to elucidate the pathogenesis of severe acute respiratory syndrome coronavirus (SARS-CoV)-2-induced lung injury and develop effective therapeutics. Clinical data indicate that severe COVID-19 most commonly manifests as viral pneumonia-induced acute respiratory distress syndrome (ARDS), a clinical entity mechanistically understood best in the context of influenza A virus-induced pneumonia. Similar to influenza, advanced age has emerged as the leading host risk factor for developing severe COVID-19. In this review we connect the current understanding of the SARS-CoV-2 replication cycle and host response to the clinical presentation of COVID-19, borrowing concepts from influenza A virus-induced ARDS pathogenesis and discussing how these ideas inform our evolving understanding of COVID-19-induced ARDS. We also consider important differences between COVID-19 and influenza, mainly COVID-19's protean clinical presentation and associated lymphopenia, the contrasting role of interferon-γ in mediating the host immune response to these viruses, and SARS-CoV-2's tropism for vascular endothelial cells, commenting on the potential limitations of influenza as a model for COVID-19. Finally, we explore hallmarks of aging that could explain the association between advanced age and susceptibility to severe COVID-19.

The spread of a novel coronavirus (severe acute respiratory syndrome coronavirus 2, or SARS-CoV-2) has challenged the capacity of healthcare systems and the public health policies of governments worldwide. [1] As of July 2020, the coronavirus disease (COVID)-19 pandemic has resulted in over 12 million cases and over 550,000 confirmed deaths, although the implementation of social distancing measures and masking have allayed the spread of the virus in many parts of the world. [2] Nevertheless, its high transmissibility portends further waves of contagion, warranting continued efforts to fully elucidate its pathogenesis and identify putative therapeutic targets. Mortality attributable to SARS-CoV-2 infection occurs mainly through the development of viral pneumonia-induced acute respiratory distress syndrome (ARDS), a clinical entity best understood in the context of influenza A virus (influenza) infection. [2, 3] While the exact mechanisms through which SARS-CoV-2 causes ARDS and how certain host factors confer an increased risk of developing severe disease remain unclear, one factor has emerged as a dominant predictor of disease severity and risk of mortality: age. [4, 5] In fact, reports from Italy and China early in the pandemic noted case-fatality rates of 15-20% among patients over age 80 compared with < 1% in patients younger than age 50. In this review we examine clinically relevant mechanisms of influenza-induced ARDS pathophysiology, discuss their relevance to COVID-19 pathophysiology and how they contrast with COVID-19-specific clinical findings, and explore hallmark biological aging processes that may underlie the age-related susceptibility to severe COVID-19.

SARS-CoV-2-an enveloped, positive-sense, single-stranded RNA virus-belongs to the Betacoronavirus genus. It shares 79% of its RNA sequence with the pathogen that caused the 2003-2004 SARS epidemic, SARS-CoV. [6] Structurally, both viruses contain a spike (S)protein on their envelope, which, following its enzymatic activation via host proteases and subsequent binding to the human ACE2 receptor, mediates viral fusion and endocytosis. [7] Once inside the cell, the viral genome is transcribed by the viral RNA-dependent RNA polymerase and then translated by host ribosomes to synthesize viral proteins. Finally, mature virions are assembled in the cytoplasm, where they are primed for exocytosis. [8] SARS-CoV has tropism for ciliated airway epithelial cells and type II pneumocytes, which is conferred by its dependence on both the human ACE2 receptor as well as the host membrane serine protease TMPRSS2 for S-protein cleavage and subsequent activation. [7] While SARS-CoV-2 shares this tropism and invasion mechanism, it has also acquired a furin cleavage site that allows S-protein fusion domain exposure by ubiquitous furin proteases. [9] These furin proteases are found on the membrane of myriad cells across the body that also express ACE2, including vascular endothelial cells. [10] This expanded tropism ultimately translates to increased infectivity as well as novel clinical consequences relative to SARS-CoV infection.

Current models of SARS-CoV-2's transmissibility have established a mean incubation period of 5 days, with viral loads peaking before symptom onset and monotonically declining thereafter. Viral loads are detectable on posterior naso/oropharyngeal swabs for a minimum of 8 days and a median of 20 days from symptom onset, according to latest reports. [11] [12] [13] [14] While the maximum duration of viral shedding remains unclear, it likely wanes by day 40 post-infection in most cases. There is significant variability in the symptoms reported during the early symptomatic phase of infection, ranging from mild constitutional symptoms such as fever, fatigue, dry cough and diarrhea, to sore throat and loss of taste; some cases remain entirely asymptomatic in this phase. [15] [16] [17] In many patients these prodromal symptoms are followed by the pulmonary phase of infection, characterized by respiratory symptoms and findings including dyspnea, radiographic pulmonary infiltrates, and hypoxemia. [14] Most morbidity and mortality related to COVID-19 occurs in the following inflammatory phase, characterized by a dysregulated immune response and hypercoagulable state that is associated with life-threatening complications, including cardiac and renal failure, cerebrovascular disease, and ARDS. [18, 19] Finally, among survivors, there follows a recovery phase, in which inflammation resolves and damaged lung tissue is repaired, ultimately restoring organ system homeostasis (Figure 1) . Of the life-threatening sequelae associated with the inflammatory phase, ARDS has been documented as the most commonly occurring, representing a substantial proportion of COVID-19 patients requiring ICU admission. [15] 

The Berlin Criteria define ARDS by acute hypoxemic respiratory failure following an acute event (such as a respiratory viral infection) that presents as bilateral pulmonary infiltrates on lung imaging in the absence of a purely cardiogenic or hydrostatic etiology. [20] ARDS is a heterogeneous clinical syndrome, encompassing a range of endotypes that require further characterization for the development of effective therapeutics. [21] Much progress has been made in understanding the pathophysiology of viral pneumonia-induced ARDS, particularly in the context of influenza. [3] The canonical understanding of influenza-induced ARDS begins with the presence of its negative-sense, single-stranded RNA genome in the cytoplasm of respiratory epithelial cells (Figure 2) . Cytoplasmic viral RNA triggers the secretion of type-I and -III interferons (IFN-I and IFN-III) and the pro-inflammatory cytokines IL-1β and IL-18 through the activation of well-conserved intracellular immune pathways such as Toll-like receptors (TLRs), mitochondria-associated anti-viral signaling (MAVS) proteins, and the NOD-, LRR-and pyrin domain-containing protein 3 (NLRP3) inflammasome. [22, 23] The induction of these anti-viral pathways results in the upregulation of interferon-stimulated genes and nuclear factor-κB-regulated genes as well as the recruitment of effector and regulatory immune cells. Alveolar macrophages respond to these cues by phagocytosing infected and apoptotic epithelial cells, promoting viral clearance, and secreting more proinflammatory and chemotactic cytokines including IL-6 and IL-8, characteristic of a proinflammatory macrophage response. [24] These lung epithelial cell and alveolar macrophage responses work synergistically to recruit other immune cell types, inducing the invasion of neutrophils and natural killer (NK) cells and the differentiation of circulating monocytes into monocyte-derived macrophages and dendritic cells (DCs).

As part of the innate immune response, neutrophils and NK cells are recruited to the lung parenchyma in response to the secretion of chemotactic cytokines, including CCL2, CCL5, CXCL8, and CXCL10. [25, 26] Neutrophils induce nonspecific epithelial cell necrosis via the secretion of many effector compounds, including neutrophil extracellular traps. While these processes exert protective effects against influenza virus and other pathogens, they also contribute to lung injury when they remain unchecked. [27] Similarly, NK cells are actively recruited during influenza infection and exert both pro-necrotic and -apoptotic effects via the secretion of cytotoxic granzymes and perforins; indeed, excessive NK cell-mediated cytotoxicity is associated with lethal influenza infection from uncontrolled lung injury. [28] Infiltrating monocyte-derived macrophages and DCs further contribute to the immune response by secreting other pro-inflammatory molecules including TNF-α and nitric oxide, known to drive influenza clearance and alveolar injury through the induction of epithelial cell apoptosis. [29, 30] DCs also bridge the innate and adaptive immune systems by sampling viral antigens from lung alveoli and migrating to draining lymph nodes. There, they act as antigen-presenting cells for naïve CD8 + and CD4 + T cells, activating them to expand and mature in an antigen-specific manner, after which they are mobilized to the lung. [31] Once in the lung, CD8 + T cells induce the lysis of cells presenting viral antigens, and CD4 + T cells modulate the inflammatory response in myriad ways, including the secretion of additional cytokines such as type-II interferon (IFN-II). [32, 33] These immune processes result in the active clearance of the influenza virus at the expense of severe lung injury from epithelial cell destruction and prolonged inflammation, manifesting as ARDS in a subset of patients. Interestingly, post-mortem studies of patients that succumbed to influenza induced-ARDS showed undetectable viral loads in most patients, suggesting that the direct cytotoxic effects of the virus are not the only drivers of mortality; the host's inability to dampen inflammation and repair damaged lung tissue contribute to a great degree. [34] These findings have generated substantial interest in the physiologic processes that mediate the resolution of inflammation and repair of lung injury and how they contribute to viral pneumonia-induced ARDS-related morbidity and mortality. Many host components responsible for mediating the recovery phase have been identified, including FOXP3 + regulatory T (Treg) cells. [35] [36] [37] [38] [39] [40] [41] [42] Treg cells are well known for their role in promoting immune self-tolerance through the negative regulation of CD4 + T cells, but they also serve other homeostatic functions, mediating resolution of inflammation by inhibiting the proinflammatory effects of macrophages and enhancing their phagocytic activity. [39, 42, 43] Treg cells also promote lung epithelial cell proliferation via the secretion of amphiregulin, a ligand of the epidermal growth factor receptor, and keratinocyte growth factor. [44, 45] These processes modulate the host immune response and help to restore lung parenchymal homeostasis. Consequently, their potential malfunction partially explains the wide spectrum of outcomes among patients with influenza virus-induced ARDS.

The heterogeneity associated with COVID-19's clinical presentation has prompted the conceptualization of novel paradigms of respiratory disease in an effort to explain the observed variability and individualize clinical management of COVID-19. [46] Nevertheless, a recent cohort study reported that as many as 85% of ICU patients with COVID-19 meet the Berlin Criteria definition of ARDS and that well-established supportive interventions for ARDS, such as low tidal volumes and prone ventilation, resulted in significant improvement in oxygenation and lung compliance. [47] It is therefore reasonable to explore other causes of viral pneumonia-induced ARDS to glean insights into severe COVID-19 while we await more disease-focused data. Accordingly, there is evidence suggesting both parallels and contrasts between influenza and SARS-CoV-2 infections. [48] Global immune signature of SARS-CoV-2. Early work performed to characterize COVID-19's host immune response suggested an immune signature consisting of elevated serum cytokines (particularly IL-1β, IL-6, and TNF-α), impaired interferon responses, and peripheral lymphopenia as markers of severe disease; other associated inflammatory serum markers include elevated levels of ferritin, lactate dehydrogenase, d-dimer, C-reactive protein, and coagulation factors. [4, 14, 49] Furthermore, transcriptional profiling of lung epithelial cells following SARS-CoV-2 and influenza infections in vitro revealed similar dampening of IFN-I and -III signaling in the host response to both of these viruses and a shared cytokine signature (including IL-6 and TNF-α). In contrast, the SARS-CoV-2-specific immune signature identified in vitro was characterized by high IFN-II signaling and chemokine expression relative to influenza. [50] Impaired interferon-I and -III responses. Both COVID-19 and influenza are associated with an impaired IFN-I and -III host response relative to other viruses, and COVID-19 severity correlates with the degree of impairment. [50, 51] The influenza and SARS-CoV genomes code for the nonstructural protein 1 (NS1), which antagonizes IFN-I and -III signaling; similarly, the SARS-CoV-2 proteins ORF6, ORF8 and its nucleocapsid also inhibit IFN-I signaling in vitro. [52] [53] [54] suggest that SARS-CoV-2 infects endothelial cells to cause inflammation (endothelialitis). [64] This observed endothelialitis supports the idea that SARS-CoV-2 has tropism for vascular endothelial cells, which express the ACE receptor. [10] Moreover, viral cytotoxicity could be playing a larger role in mediating severe COVID-19 than in influenza, since post-mortem detection of replicating virus is less frequent in the latter. [ [50] Some have suggested that the IL-6-to-IFN-γ ratio could be used as a clinical tool to stratify patients by their relative risk of developing severe COVID-19, and preliminary analyses of this ratio as a risk-stratifying measure for severe COVID-19 showed promising results. [69] Nevertheless, a better understanding of the role of IFN-γ in driving severe disease and the validation of the IL-6-to-IFN-γ ratio in larger cohorts will be required before its deployment as a reliable clinical tool.

Severe COVID-19 is associated with lymphopenia that disproportionately affects the T rather than B cell compartment. [64, 73, 74] . Finally, some hypothesize this lymphopenia to be a direct consequence of the expanded tropism of SARS-CoV-2, which could confer cytotoxicity to T cell populations; however, such tropism remains unverified. As lymphopenia is being considered for patient risk stratification, elucidating the etiology of COVID-19-associated lymphopenia is crucial for our understanding of COVID-19 pathogenesis and efforts to identify patients at risk of developing severe disease. [75] Transmissibility profile and host risk factors for severe disease. Current models of COVID-19's transmissibility recapitulate an influenza-like profile of viral shedding, suggesting that contact precautions for influenza could prove efficacious in the context of COVID-19. [12] Importantly, there are key differences between these two viruses with respect to identified host risk factors for severe disease. For example, influenza-induced ARDS carries a female predominance, while COVID-19-induced ARDS is mostly associated with male sex, suggesting that they exploit different host susceptibilities to enhance their pathogenicity. [76, 77] Regardless, advanced age still remains the main predictor for the development of severe disease associated with both pathogens, signifying that our knowledge of advanced age as a risk factor for influenza-induced ARDS can inform our understanding of age in predisposing to severe COVID-19.

Advanced age is associated with an increased risk of developing life-threatening infections. [78] Indeed, almost 90% of influenza-related mortality and a disproportionate fraction of COVID-19-related mortality occurs in individuals over the age of 65. [4, 5, 79, 80] This age-related susceptibility to severe disease does not arise solely because of prolonged exposure to environmental and host risk factors, such as tobacco smoke or primary hypertension, but also through the development of maladaptive physiological processes that affect an individual's ability to maintain homeostasis when faced with a stressor. These processes have been coined the hallmarks of aging and have been broadly associated with an age-related susceptibility to stress, also known as homeostenosis. [81, 82] The increasingly older world population and its myriad age-related comorbidities have generated substantial interest in understanding the pathophysiology of these hallmarks of aging, particularly as they relate to the risk of severe COVID-19. While their influence has not been elucidated in the context of SARS-CoV-2 infection, our current knowledge of their role in influenza provides insight into why aging is a risk factor for the development of severe COVID-19 (Figure 3) .

Epigenetic alterations and mitochondrial dysfunction. Advanced age is associated with changes in the epigenetic and metabolic landscape of immune cells that mediate the host response to viral pneumonia-induced ARDS, including Treg cells. [39] The pro-repair function of Treg cells is associated with DNA hypomethylation of Treg cell lineage-specific loci.

in a murine influenza model, suggesting that DNA methylation is required to maintain the Treg cell lineage over the lifespan but impairs Treg cell reparative function after lung injury. [40] While alterations in Treg cell function and numbers have been shown to occur with aging, the mechanisms through which these changes occur remain unclear; however, recent studies suggest they could be mediated by the accumulation of toxic metabolites and reactive oxygen species caused by the mitochondrial dysfunction associated with aging. [83] For example, intracellular accumulation of the metabolite L-2-hydroxyglutarate from its synthesis during hypoxia and other states of mitochondrial dysfunction induces DNA hypermethylation and impairs suppressive function in Treg cells. [84] Such metabolite accumulation could ultimately inhibit Treg cell-dependent ARDS recovery by repressing the expression of key loci associated with Treg cell pro-resolution and pro-repair pathways.

Given the age-related phenomenon of mitochondrial dysfunction, irrespective of its proximate cause, it is plausible that similar phenomena are occurring across other cell types also required for viral ARDS resolution.

Telomere attrition and cellular senescence. Aging is associated with the erosion of chromosomal telomeres from successive cellular replication (telomere attrition) and the concomitant cell cycle arrest of somatic cells (cellular senescence), including monocytes and lymphocytes. Monocytes from aged mice suffer from an inability to properly phagocytose bacterial pathogens, while producing significantly higher levels of TNF-α relative to young mice. These findings correlate with the telomere length of monocytes, which are shorter in the elderly, suggesting an age-related impairment in pathogen clearance and excessive TNF-α-mediated apoptosis that is in part mediated by telomere attrition. [85] These agerelated phenomena also affect naïve T and B cell numbers, manifesting as low peripheral blood counts of these cells in older hosts. [86] Coupled with the process of thymic involution, age-related depletion of naïve T cell counts poses a substantial impediment for the adaptive immune system's ability to generate antigen-specific memory lymphocytes. [87] Accordingly, a recent GWAS of genetic factors linked to severe COVID-19 susceptibility identified a risk allele associated with decreased levels of CXCR6 expression, which is a chemokine receptor expressed in tissue resident memory T cells. [88] This finding supports the hypothesis that impaired memory T cell function predisposes to developing severe COVID-19. Age-related naïve T cell deficiency is also hypothesized to play a role in the prolonged hospital stays and increased susceptibility to severe disease in the aging population affected by influenza-induced ARDS.

[89] Finally, naïve T cell depletion also underlies the decreased efficacy of seasonal influenza vaccines observed with increasing age, restricting preventive therapeutic alternatives for older adults. [80] Altered intercellular communication. The replicative senescence related to aging affects a variety of somatic cells and is associated with a shift toward a basal, chronic secretion of pro-inflammatory cytokines, a phenomenon termed the senescence-associated secretory phenotype (SASP). [82] According to the senescence hypothesis, accumulation of these SASP-like cells throughout aging results in the persistent recruitment and activation of effector immune cells that perturb the local communication of the pro-and anti-inflammatory arms of the immune system, inducing tissue damage and impeding tissue repair. [90] Accordingly, selective depletion of stress-induced senescent cells in vivo attenuated the SASP-related transcriptional signal following acute lung injury and improved physical function in mice, suggesting that the accumulation of senescent alveolar epithelial cells ultimately compromises the host's ability to properly recover from acute lung injury. [91] Such pro-inflammatory states may also explain the predisposition to many age-associated pathologies, including primary hypertension, the comorbidity most strongly correlated with an individual's risk for developing severe COVID-19. [92] 

Our evolving understanding of COVID-19 suggests that the pathogenesis of influenza provides insights into COVID-19, particularly with regard to the impaired IFN-I and -III host response. However, findings in influenza fall short in explaining severe COVID-19's distinct clinical course, endothelialitis, the role of IFN-II, and the lymphopenia associated with severe COVID-19. We suggest that such differences between these two infections represent SARS-CoV-2-specific virulence mechanisms that, if elucidated, could inform the development of novel therapeutic strategies. Therefore, we contend that these differences need to be accounted for and should be a focus for ongoing research efforts. We also speculate that the severe COVID-19-specific immune signature, coupled with age-related maladaptive phenomena, could impede the host's ability to dampen the inflammatory phase of severe COVID-19 and resolve lung injury, contributing to the protracted ICU care episodes and the attendant morbidity and mortality associated with prolonged ICU stays among older adults.

Given the interdependent and synergistic nature of these hallmarks of aging, we suggest that these hallmarks' influence on relative susceptibility to developing severe COVID-19 should be studied in concert. Ultimately, the mechanistic associations between the biology of aging and the relative susceptibility to severe viral pneumonia-induced ARDS carry substantial clinical implications that require careful consideration in future efforts to develop population-specific preventive and therapeutic interventions for COVID-19. 

China Novel Coronavirus Investigating Research Team. A Novel Coronavirus from Patients with Pneumonia in China

World Health Organization. Coronavirus disease (COVID-19) Pandemic

Influenza virus-induced lung injury: pathogenesis and implications for treatment

Clinical and immunological features of severe and moderate coronavirus disease 2019

Case-Fatality Rate and Characteristics of Patients Dying in Relation to COVID-19 in Italy

Coronaviridae Study Group of the International Committee on Taxonomy of Viruses. The species Severe acute respiratory syndrome-related coronavirus: classifying 2019-nCoV and naming it SARS-CoV-2

SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor

The molecular biology of intracellular events during Coronavirus infection cycle

Structure, Function, and Antigenicity of the SARS-CoV-2 Spike Glycoprotein

Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus. A first step in understanding SARS pathogenesis

Temporal profiles of viral load in posterior oropharyngeal saliva samples and serum antibody responses during infection by SARS-CoV-2: an observational cohort study

Temporal dynamics in viral shedding and transmissibility of COVID-19

SARS-CoV-2 Viral Load in Upper Respiratory Specimens of Infected Patients

Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study

Latin American Network of Coronavirus Disease. Clinical, laboratory and imaging features of COVID-19: A systematic review and meta-analysis

Clinical features of patients infected with 2019 novel coronavirus in Wuhan

Clinical characteristics of 24 asymptomatic infections with COVID-19 screened among close contacts in Nanjing

Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and the Central Nervous System

Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study

Acute respiratory distress syndrome: the Berlin Definition

Subphenotypes in acute respiratory distress syndrome: latent class analysis of data from two randomised controlled trials

Interferon induction and function at the mucosal surface

Type I IFN triggers RIG-I/TLR3/NLRP3-dependent inflammasome activation in influenza A virus infected cells

Innate immune response of human alveolar macrophages during influenza A infection

A Role for Neutrophils in Viral Respiratory Disease

Natural Killer Cell Recruitment to the Lung During Influenza A Virus Infection Is Dependent on CXCR3, CCR5, and Virus Exposure Dose

Excessive neutrophils and neutrophil extracellular traps contribute to acute lung injury of influenza pneumonitis

Critical role of natural killer cells in lung immunopathology during influenza infection in mice

Macrophage plasticity and polarization: in vivo veritas

TNF/iNOS-producing dendritic cells are the necessary evil of lethal influenza virus infection

Clearance of influenza virus from the lung depends on migratory langerin+CD11b-but not plasmacytoid dendritic cells

CD8(+) T cells clear influenza virus by perforin or Fas-dependent processes

T cell responses during influenza infection: getting and keeping control

pandemic influenza A (H1N1): pathology and pathogenesis of 100 fatal cases in the United States

Immunological priming requires regulatory T cells and IL-10-producing macrophages to accelerate resolution from severe lung inflammation

Enhanced resolution of experimental ARDS through IL-4-mediated lung macrophage reprogramming

Foxp3+ regulatory T cells promote lung epithelial proliferation

Immunometabolism of pro-repair cells

Regulatory T cell DNA methyltransferase inhibition accelerates resolution of lung inflammation

Multidimensional assessment of alveolar T cells in critically ill patients

CD4+CD25+Foxp3+ Tregs resolve experimental lung injury in mice and are present in humans with acute lung injury

Regulatory T Cells Promote Macrophage Efferocytosis during Inflammation Resolution

A Distinct Function of Regulatory T Cells in Tissue Protection

Foxp3(+) Regulatory T Cell Expression of Keratinocyte Growth Factor Enhances Lung Epithelial Proliferation

COVID-19 pneumonia: different respiratory treatments for different phenotypes?

Respiratory Pathophysiology of Mechanically Ventilated Patients with COVID-19: A Cohort Study

Comparison of Hospitalized Patients With ARDS Caused by COVID-19 and H1N1

Endotheliopathy in COVID-19-associated coagulopathy: evidence from a single-centre, cross-sectional study

Imbalanced Host Response to SARS-CoV-2 Drives Development of COVID-19

Heightened Innate Immune Responses in the Respiratory Tract of COVID-19 Patients

Influenza virus non-structural protein 1 (NS1) disrupts interferon signaling

Coronavirus non-structural protein 1 is a major pathogenicity factor: implications for the rational design of coronavirus vaccines

The ORF6, ORF8 and nucleocapsid proteins of SARS-CoV-2 inhibit type I interferon signaling pathway

Dysregulated Type I Interferon and Inflammatory Monocyte-Macrophage Responses Cause Lethal Pneumonia in SARS-CoV-Infected Mice

IFNlambda is a potent anti-influenza therapeutic without the inflammatory side effects of IFNalpha treatment

Interferonlambda modulates dendritic cells to facilitate T cell immunity during infection with influenza A virus

Interferon-lambda Mediates Non-redundant Front-Line Antiviral Protection against Influenza Virus Infection without Compromising Host Fitness

Type III interferons disrupt the lung epithelial barrier upon viral recognition

Inhibition of SARS-CoV-2 by type I and type III interferons

Whole-Exome Sequencing Reveals Mutations in Genes Linked to Hemophagocytic Lymphohistiocytosis and Macrophage Activation Syndrome in Fatal Cases of H1N1 Influenza

Macrophage activation syndrome: early diagnosis is key

The Immunology of Macrophage Activation Syndrome

Pulmonary Vascular Endothelialitis, Thrombosis, and Angiogenesis in Covid-19

Endothelial cell infection and endotheliitis in COVID-19

Is a "Cytokine Storm" Relevant to COVID-19?

Lack of IFNgamma signaling attenuates spread of influenza A virus in vivo and leads to reduced pathogenesis

Gamma interferon regulates contraction of the influenza virusspecific CD8 T cell response and limits the size of the memory population

High IL-6/IFN-gamma ratio could be associated with severe disease in COVID-19 patients

CD69 acts downstream of interferon-alpha/beta to inhibit S1P1 and lymphocyte egress from lymphoid organs

Complex Immune Dysregulation in COVID-19 Patients with Severe Respiratory Failure

Comparison of Hospitalized Patients With ARDS Caused by COVID-19 and H1N1

Postmortem examination of COVID-19 patients reveals diffuse alveolar damage with severe capillary congestion and variegated findings in lungs and other organs suggesting vascular dysfunction

Bronchoalveolar lavage findings in severe COVID-19 pneumonia

Lymphopenia predicts disease severity of COVID-19: a descriptive and predictive study

Populations at risk for severe or complicated influenza illness: systematic review and meta-analysis

Risk Factors Associated With Acute Respiratory Distress Syndrome and Death in Patients With Coronavirus Disease

Epidemiology of severe sepsis in the United States: Analysis of incidence, outcome, and associated costs of care

Epidemiology of Seasonal Influenza: Use of Surveillance Data and Statistical Models to Estimate the Burden of Disease

Influenza Illness and Hospitalizations Averted by Influenza Vaccination in the United States

The hallmarks of aging

Molecular and physiological manifestations and measurement of aging in humans

DNA methylation as a transcriptional regulator of the immune system

Mitochondrial complex III is essential for suppressive function of regulatory T cells

Aging is associated with chronic innate immune activation and dysregulation of monocyte phenotype and function

The effect of ageing on human lymphocyte subsets: comparison of males and females

The effect of age on thymic function

Genomewide Association Study of Severe Covid-19 with Respiratory Failure

The senescence-associated secretory phenotype: the dark side of tumor suppression

Elimination of senescent cells by beta-galactosidase-targeted prodrug attenuates inflammation and restores physical function in aged mice

Low-grade inflammation and hypoadiponectinaemia have an additive detrimental effect on aortic stiffness in essential hypertensive patients